Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GRCE)

15 filings reported holding GRCE - Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q4 2024.
Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GRCE) has 15 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 2.09M shares of 14.1M outstanding shares and own 14.86% of the company stock.
Largest 10 shareholders include ADAR1 Capital Management, LLC (774K shares), AIGH Capital Management LLC (521K shares), BANK OF AMERICA CORP /DE/ (495K shares), VANGUARD GROUP INC (225K shares), RENAISSANCE TECHNOLOGIES LLC (43K shares), CITADEL ADVISORS LLC (23.7K shares), NATIONAL BANK OF CANADA /FI/ (2.72K shares), MORGAN STANLEY (1.88K shares), Tower Research Capital LLC (TRC) (1.5K shares), and Royal Bank of Canada (543 shares).
This table shows the top 15 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.